

Substitute for form 1449/PTO			<b>Complete If Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	09/402,614	
			Filing Date	March 1, 2000	
			First Named Inventor	Gail P. RISBRIDGER	
			Art Unit	1642	
			Examiner Name	L. Yao	
Sheet	1	of	2	Attorney Docket Number	229752000800

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
	1.	WO-86/00078	01-03-1986	Monash University; Prince Henry's Hospital; St. Vincent's Institute of Medical Research; Biotechnology Australia Proprietary Limited		
	2.	WO-89/11862	12-14-1989	Biotechnology Australia Pty. Ltd.; Monash University; Monash Medical Centre; St. Vincent's Institute of Medical Research		
	3.	WO-92/04913	04-02-1992	Children's Hospital Medical Center of Northern California		

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 601.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
	4.	Haywood-Reid et al. (1997). "Quantification of Integrin Subunits on Human Prostatic Cell Lines--Comparison of Nontumorigenic and Tumorigenic Lines," <i>The Prostate</i> 31(1): 1-8.				
	5.	Kramer et al. (1993). "Prostate Cancer Screening: What We Know and What We Need to Know," <i>Annals of Internal Medicine</i> 119(9): 914-923.				
	6.	Lebrun et al. (March 1997). "Activin and Inhibin Have Antagonistic Effects on Ligand-Dependent Heteromerization of the Type I and Type II Activin Receptors and Human Erythroid Differentiation," <i>Molecular and Cellular Biology</i> 17(3): 1682-1691.				
	7.	Mellor et al. (1998). "Loss of the Expression and Localization of Inhibin $\alpha$ -Subunit in High Grade Prostate Cancer," <i>Journal of Clinical Endocrinology and Metabolism</i> 83(3): 969-975.				
	8.	Rinker-Schaeffer et al. (1994). "Molecular and Cellular Changes Associated With the Acquisition of Metastatic Ability by Prostatic Cancer Cells," <i>The Prostate</i> 25(5): 249-265.				
	9.	Risbridger, G.P. (1998). "Recent progress in our understanding of inhibin in the prostate gland," <i>Journal of Endocrinology</i> 157(1): 1-4.				
	10.	Sheth et al. (1981). "Inhibin in the Human Prostate," <i>Archives of Andrology</i> 6(4):317-321.				
	11.	Supplementary Partial European Search Report dated March 13, 2003, directed to counterpart EP application no. 98916648.3.				
	12.	Supplementary Partial European Search Report dated August 14, 2003, directed to counterpart EP application no. 98916648.3.				

Substitute for form 1449/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	09/402,614
				Filing Date	March 1, 2000
				First Named Inventor	Gail P. RISBRIDGER
				Art Unit	1642
				Examiner Name	L. Yao
Sheet	2	of	2	Attorney Docket Number	229752000800

	13.	Thomas et al. (1997). "Expression and Localization of Activin Subunits and Follistatins in Tissues from Men with High Grade Prostate Cancer," <i>Journal of Clinical Endocrinology and Metabolism</i> 82(11): 3851-3858.	
	14.	Wang et al. (1996). "Activin Inhibits Basal and Androgen-Stimulated Proliferation and Induces Apoptosis in the Human Prostatic Cancer Cell Line, LNCaP," <i>Endocrinology</i> 137(12): 5476-5483.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.